Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation

Published:2020-07-06 Issue:9 Volume:18 Page:2205-2208
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Harkins Druzgal Colleen¹,Kizilocak Hande²,Brown Joshua³,Sennett Margaret¹,Young Guy¹⁴^ORCID

Affiliation:

1. Division of Hematology‐Oncology Department of Pediatrics University of Virginia Health System Charlottesville VA USA

2. Hemostasis and Thrombosis Center Children’s Hospital Los Angeles Los Angeles CA USA

3. Department of Pathology and Laboratory Medicine Children’s Hospital Los Angeles Los Angeles CA USA

4. Keck School of Medicine University of Southern California Los Angeles CA USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14957

Reference9 articles.

1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

2. How I treat children with haemophilia and inhibitors

3. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

4. www.Hemlibra.com accessed May 5 2020.

5. Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial;Blood;2024-05-30

2. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review;Research and Practice in Thrombosis and Haemostasis;2024-05

3. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers;Frontiers in Oncology;2024-04-19

4. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies;Research and Practice in Thrombosis and Haemostasis;2024-02

5. Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis;Sao Paulo Medical Journal;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3